Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Hammers Discusses Immunotherapy in RCC

Hans Hammers, MD, PhD
Published: Wednesday, Mar 01, 2017



Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

In November 2015, nivolumab (Opdivo) was approved by the FDA for the second-line treatment of patients with RCC. Response rates are around 20% with moderate activity, says Hammers, but this can be improved with combinations.

Nivolumab in combination with targeted agents such as VEGF inhibitors, or selective agents such as axitinib (Inlyta), could be promising, says Hammers. Durability and quality of response should be evaluated closely, though, to determine the synergy of the given agents.

PD-1 inhibitors and CTLA-4 inhibitors are also being looked at in combination in the phase III CheckMate-214 trial.
 


Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses immunotherapy in renal cell carcinoma (RCC).

In November 2015, nivolumab (Opdivo) was approved by the FDA for the second-line treatment of patients with RCC. Response rates are around 20% with moderate activity, says Hammers, but this can be improved with combinations.

Nivolumab in combination with targeted agents such as VEGF inhibitors, or selective agents such as axitinib (Inlyta), could be promising, says Hammers. Durability and quality of response should be evaluated closely, though, to determine the synergy of the given agents.

PD-1 inhibitors and CTLA-4 inhibitors are also being looked at in combination in the phase III CheckMate-214 trial.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x